

A\$2.6m R&D rebate received

Genetic Signatures Limited (ASX: GSS, “**Genetic Signatures**” or the “**Company**”) is pleased to announce that it has received a refund from the Australian Tax Office under its Research and Development (“**R&D**”) tax incentive program of A\$2,578,627.

The R&D tax incentive is an Australian Government program under which companies receive cash refunds for eligible expenditure on R&D.

About Genetic Signatures Limited: Genetic Signatures is a specialist molecular diagnostics (MDx) company focused on the development and commercialisation of its proprietary platform technology, **3base**[™]. Genetic Signatures designs and manufactures a suite of real-time Polymerase Chain Reaction (PCR) based products for the routine detection of infectious diseases under the *EasyScreen*[™] brand. Genetic Signatures’ proprietary MDx **3base**[™] platform technology provides high-volume hospital and pathology laboratories the ability to screen for a wide array of infectious pathogens, with a high degree of specificity, in a rapid throughput (time-to-result) environment. Genetic Signatures’ current target markets are major hospital and pathology laboratories undertaking infectious disease screening.

For further information, see our website (www.geneticsignatures.com) or contact us as below:

Dr John Melki
Chief Executive Officer
john.melki@geneticsignatures.com
T: +61 (0)2 9870 7580

Peter Manley
Chief Financial Officer
peter.manley@geneticsignatures.com